The association of UGT1A1*6 and UGT1A1*28 with irinotecan-induced neutropenia in Asians: a meta-analysis

References

• Akiyama Y, Fujita K, Nagashima F, et al. (2008). Genetic testing for UGT1A1*28 and *6 in Japanese patients who receive irinotecan chemotherapy. Ann Oncol 19:2089–90
   PubMedGoogle Scholar
• Choi YH, Kim TW, Kim KP, et al. (2012). A phase II study of clinical outcomes of 3-week cycles of irinotecan and s-1 in patients with previously untreated metastatic colorectal cancer: influence of the UGT1A1 and CYP2A6 polymorphisms on clinical activity. Oncology 82:290–7
   PubMedGoogle Scholar
• Fuchs CS, Moore MR, Harker G, et al. (2003). Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol 21:807–14
   PubMed Web of Science ®Google Scholar
• Fukui T, Mitsufuji H, Kubota M, et al. (2011). Prevalence of topoisomerase I genetic mutations and UGT1A1 polymorphisms associated with irinotecan in individuals of Asian descent. Oncol Lett 2:923--8
   PubMed Web of Science ®Google Scholar
• Gao J, Zhou J, Li Y, et al. (2013). UGT1A1*6/*28 polymorphisms could predict irinotecan-induced severe neutropenia not diarrhea in Chinese colorectal cancer patients. Med Oncol 30:604--9
   PubMedGoogle Scholar
• Hall D, Ybazeta G, Destro-Bisol G, et al. (1999). Variability at the uridine diphosphate glucuronosyltransferase 1A1 promoter in human populations and primates. Pharmacogenet Genome 9:591–606
   PubMedGoogle Scholar
• Han JY, Lim HS, Shin ES, et al. (2006). Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J Clin Oncol 24:2237–44
   PubMed Web of Science ®Google Scholar
• Hazama S, Nagashima A, Kondo H, et al. (2010). Phase I study of irinotecan and doxifluridine for metastatic colorectal cancer focusing on the UGT1A1*28 polymorphism. Cancer Sci 101:722–7
   PubMedGoogle Scholar
• Hu ZY, Yu Q, Pei Q, et al. (2010). Dose-dependent association between UGT1A1*28 genotype and irinotecan-induced neutropenia: low doses also increase risk. Clin Cancer Res 16:3832–42
   PubMed Web of Science ®Google Scholar
• Inoue K, Sonobe M, Kawamura Y, et al. (2012). Polymorphisms of the UDP-glucuronosyl transferase 1A genes are associated with adverse events in cancer patients receiving irinotecan-based chemotherapy. Tohoku J Exp Med 229:107–14
   Google Scholar
• Jo JC, Lee JL, Ryu MH, et al. (2012). Phase II and UGT1A1 genotype study of irinotecan dose escalation as salvage therapy for advanced gastric cancer. Br J Cancer 106:1591–7
   PubMedGoogle Scholar
• Liu X, Cheng D, Kuang Q, et al. (2013). Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians. Pharmacogenom J. doi: 10.1038/tpj.2013.10
   Google Scholar
• Marsh S, Hoskins JM. (2010). Irinotecan pharmacogenomics. Pharmacogenomics 11:1003–10
   PubMed Web of Science ®Google Scholar
• Minami H, Sai K, Saeki M, et al. (2007). Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28. Pharmacogenet Genom 17:497–504
   PubMed Web of Science ®Google Scholar
• Okazaki K, Watanabe T, Saito I, et al. (2012). Examination of factors affecting adverse reactions and dosage reduction in UGT1A1 genotyped patients: a retrospective survey of irinotecan. Yakugaku zasshi: J Pharmaceut Soc Jpn 132:231--6
   PubMedGoogle Scholar
• Okuyama Y, Hazama S, Nozawa H, et al. (2011). Prospective phase II study of FOLFIRI for mCRC in Japan, including the analysis of UGT1A1*28/*6 polymorphisms. Japan J Clin Oncol 41:477–82
   PubMedGoogle Scholar
• Onoue M, Terada T, Kobayashi M, et al. (2009). UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients. Int J Clin Oncol 14:136–42
   PubMed Web of Science ®Google Scholar
• Premawardhena A, Fisher CA, Liu YT, et al. (2003). The global distribution of length polymorphisms of the promoters of the glucuronosyltransferase 1 gene (UGT1A1): hematologic and evolutionary implications. Blood Cells Mol Dis 31:98–101
   PubMed Web of Science ®Google Scholar
• Sai K, Saito Y, Sakamoto H, et al. (2008). Importance of UDP-glucuronosyltransferase 1A1*6 for irinotecan toxicities in Japanese cancer patients. Cancer Lett 261:165–71
   PubMed Web of Science ®Google Scholar
• Satoh T, Ura T, Yamada Y, et al. (2011). Genotype‐directed, dose‐finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms. Cancer Sci 102:1868–73
   PubMed Web of Science ®Google Scholar
• Seo BG, Kwon HC, Oh SY, et al. (2009). Comprehensive analysis of excision repair complementation group 1, glutathione S-transferase, thymidylate synthase and uridine diphosphate glucuronosyl transferase 1A1 polymorphisms predictive for treatment outcome in patients with advanced gastric cancer treated with FOLFOX or FOLFIRI. Oncology Rep 22:127–36
   PubMedGoogle Scholar
• Staessen JA, Kuznetsova T, Acceto R, on behalf of the OASIS-HT Investigators. (2005). FDA clears Third Wave pharmacogenetic test. Pharmacogenomics 6:671–2
   Google Scholar
• Sugiyama T, Hirose T, Kusumoto S, et al. (2010). The UGT1A1*28 genotype and the toxicity of low-dose irinotecan in patients with advanced lung cancer. Oncology Res 18:337–42
   PubMedGoogle Scholar
• Sunakawa Y, Ichikawa W, Fujita K, et al. (2011). UGT1A1*1/*28 and *1/*6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer. Cancer Chemother Pharmacol 68:279–84
   PubMedGoogle Scholar
• Takano M, Kato M, Yoshikawa T, et al. (2009). Clinical significance of UDP-glucuronosyltransferase 1A1*6 for toxicities of combination chemotherapy with irinotecan and cisplatin in gynecologic cancers: a prospective multi-institutional study. Oncology 76:315–21
   PubMed Web of Science ®Google Scholar
• Thakkinstian A, McElduff P, D’Este C, et al. (2005). A method for meta-analysis of molecular association studies. Stat Med 24:1291–306
   PubMed Web of Science ®Google Scholar
• Wang Y, Shen L, Xu N, et al. (2012). UGT1A1 predicts outcome in colorectal cancer treated with irinotecan and fluorouracil. World J Gastroenterol: WJG 18:6635–44
   PubMed Web of Science ®Google Scholar
• Yamamoto N, Takahashi T, Kunikane H, et al. (2008). Phase I/II pharmacokinetic and pharmacogenomic study of UGT1A1 polymorphism in elderly patients with advanced non-small cell lung cancer treated with irinotecan. Clin Pharmacol Therapeut 85:149–54
   PubMedGoogle Scholar
• Yong WP, Innocenti F, Ratain MJ. (2006). The role of pharmacogenetics in cancer therapeutics. Br J Clin Pharmacol 62:35–46
   PubMed Web of Science ®Google Scholar
• Zhou CF, Ma T, Su Y, et al. (2013). UGT1A1 gene polymorphisms and the toxicities of FOLFIRI in Chinese Han patients with gastrointestinal cancer. Anti-Cancer Agents Med Chem-Anti-Cancer Agents 13:235–41
   PubMedGoogle Scholar
• Zintzaras E. (2010). The generalized odds ratio as a measure of genetic risk effect in the analysis and meta-analysis of association studies. Statist Appl Genet Mol Biol 2010;9:Article 21
   Google Scholar
• Zintzaras E. (2013). Examining the stability of genetic risk effect as evidence accumulates in the context of meta-analysis. Comput Biol Med 43:1293–9
   PubMedGoogle Scholar
• Zintzaras E, Lau J. (2008). Synthesis of genetic association studies for pertinent gene-disease associations requires appropriate methodological and statistical approaches. J Clin Epidemiol 61:634–45
   PubMed Web of Science ®Google Scholar